rHEALTH point-of-care device gets NIH support

rHEALTH announced on October 8, 2020 that it was awarded a $1.5 million USD “Direct to Phase II” grant from the National Institutes of Health (NIH) to continue developing its point-of-care technology to monitor FVIII and emicizumab levels in hemophilia A patients. The WFH has agreed to advise rHEALTH in this endeavour, which is in line with our strategic priority of supporting the development of a point-of care device that would make diagnosis easier for unidentified Hemophilia A populations across the world. To read the full press release, please click here.